Brad L. Schoenfeld

KO client Kailera Therapeutics, a clinical-stage biotechnology company focused on elevating the next era of obesity care, recently announced positive topline data from two Phase 3 clinical trials for people living with obesity or type 2 diabetes. KO partner Brad Schoenfeld and attorney John Shearer represented Kailera in getting the…

KO client Elpida Therapeutics, a nonprofit biotechnology company dedicated to developing treatments for ultra-rare pediatric neurological diseases, recently announced that it has entered into an assignment and license agreement with Ionis Pharmaceuticals for ION283, an investigational antisense oligonucleotide (ASO) therapy for Lafora disease. The agreement is expected to advance the…

KO client Modella AI, a leader in artificial intelligence for life sciences, was recently acquired by AstraZeneca, expanding the companies’ existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca’s global oncology portfolio. The acquisition will integrate Modella AI’s generative and agentic AI platform…

KO client Finding Hope for Frizzle (FRRS1L), a parent-led nonprofit organization working to develop a lifesaving treatment for FRRS1L patients, and Apertura Gene Therapy recently announced a license agreement to develop a gene therapy using Apertura’s TfR1 CapX technology. “Although FRRS1L is a horrible and devastating disease robbing children of…

For life sciences startups, many groundbreaking innovations start in university labs. But transforming that research into real-world impact requires navigating the often-complex process of university technology licensing. At Boulder Startup Week 2025, KO partner Brad Schoenfeld joined the University of Colorado’s Annalissa Philbin to share practical guidance from both the…

The life sciences and pharmaceutical industries are experiencing significant transformation, driven by digital advancements and scientific innovations. Emerging companies face the challenge of rapidly bringing new products to market, often relying on partnerships that necessitate the swift execution of numerous contracts. Managing this influx can overwhelm in-house legal teams, diverting…

KO client Whitecap Biosciences, which is developing two innovative therapies for potential use in glaucoma and geographic atrophy, was recently acquired by Bausch + Lomb, a leading global eye health company to strengthen its expanding clinical stage pipeline. “Glaucoma and geographic atrophy can cause severe vision loss, with many patients…

KO client Cloudbreak Pharma, an innovative clinical-stage ophthalmology biotechnology company, recently announced that it has entered into a licensing agreement with Santen, a specialized company dedicated to eye health, to develop, manufacture, and commercialize its topical pterygium treatment. Cloudbreak founder and CEO Jinsong Ni said: “We are excited to partner…